Uta Mommert

2 weeks ago | european-biotechnology.com | Uta Mommert

As human space exploration eyes destinations beyond the Moon, the challenge of provisioning astronauts is becoming an ever-growing concern. Feeding a single astronaut in orbit currently costs an estimated £20,000 per day. Hauling all supplies from Earth simply won’t scale for deep-space missions. An alternative source of these supplies is needed – and microbes, yeasts in particular, could fit the bill.

3 weeks ago | european-biotechnology.com | Uta Mommert

Paris-based start-up Standing Ovation’s patented process converts the serums supplied by Bel into functional casein proteins. The approach offers a sustainable alternative to conventional dairy supply chains. Bel hopes that, in addition to reducing waste and creating an additional valorisation stream, it will also promote a circular economy within the industry.

1 month ago | european-biotechnology.com | Uta Mommert

The Dutch government outlined its national ambition in the Cabinet Vision on Biotechnology, aiming to harness biotechnology to achieve progress in public health, the circular economy, and food security. The vision, endorsed by the Council of Ministers following a proposal by Minister of Economic Affairs, Dirk Beljaarts, and State Secretary for Infrastructure and Water Management C.A. Jansen, points to the country’s longstanding expertise in biotechnology.

2 months ago | european-biotechnology.com | Uta Mommert

Gene therapy has been making significant strides in recent years. However, there’s a major hurdle holding it back: manufacturing. Copenhagen-based Fuse Vectors has set out to change the game with its innovative approach. At the heart of Fuse Vector are its co-founders, Benjamin Blaha and Jordan Turnbull.

Feb 4, 2025 | european-biotechnology.com | Uta Mommert

The BioEconomy Fund I is a global health fund that focuses on business-to-business (B2B) alternatives that substitute unsustainable products with scalable, cost-efficient options. It is backed by high-caliber institutional investors such as KfW Capital, Novo Holdings, Rentenbank, and Aurae Impact, along with new supporters ABN AMRO Bank and EIFO. The BioEconomy Fund I expects to reach an ambitious final close anticipated near its €200m hard cap.